Adjunctive therapy for intractable epilepsy with ethotoin.
In a retrospective study, records of 46 patients (24 women and 22 men aged 17-51 years; mean 29.2 years), who had been treated with ethotoin (EHN) as adjunctive therapy for control of intractable seizures were reviewed. Overall, approximately 51% of this highly selected patient population had a reduction greater than 50% in overall seizure frequency 1 month after initiation of treatment. This was reduced to approximately 25% for the last 3 months of follow-up (mean follow-up period 10.6 months). Tonic seizure frequency was reduced most dramatically, by greater than 50%, in 60% of patients at 1 month and in 35% of patients for the last 3 months of follow-up. This study suggests that prospective controlled trials of EHN, especially for tonic seizures, are needed.
Biton
V
V
Department of Neurology, University of Minnesota, Minneapolis.
Gates
J R
JR
Ritter
F J
FJ
Loewenson
R B
RB
D000293:Adolescent; D000328:Adult; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000627:therapeutic use; D012189:Retrospective Studies
D006827:Hydantoins; D010672:Phenytoin